VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
---|---|---|---|---|---|---|---|---|
TVIS30058493 | HIV | ENSG00000051382.10 | protein_coding | PIK3CB | Yes | No | 5291 | P42338 |
TVIS20065494 | HPV | ENSG00000051382.10 | protein_coding | PIK3CB | Yes | No | 5291 | P42338 |
TVIS44005203 | HTLV-1 | ENSG00000051382.10 | protein_coding | PIK3CB | Yes | No | 5291 | P42338 |
TVIS44016010 | HTLV-1 | ENSG00000051382.10 | protein_coding | PIK3CB | Yes | No | 5291 | P42338 |
TVIS44016011 | HTLV-1 | ENSG00000051382.10 | protein_coding | PIK3CB | Yes | No | 5291 | P42338 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
Gene | PIK3CB |
---|---|
DrugBank ID | DB12483 |
Drug Name | Copanlisib |
Target ID | BE0002407 |
UniProt ID | P42338 |
Regulation Type | inhibitor |
PubMed IDs | 29127587; 30147333 |
Citations | Markham A: Copanlisib: First Global Approval. Drugs. 2017 Dec;77(18):2057-2062. doi: 10.1007/s40265-017-0838-6.@@Mensah FA, Blaize JP, Bryan LJ: Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date. Onco Targets Ther. 2018 Aug 13;11:4817-4827. doi: 10.2147/OTT.S142264. eCollection 2018. |
Groups | Approved; Investigational |
Direct Classification | Quinazolinamines |
SMILES | COC1=C(OCCCN2CCOCC2)C=CC2=C1N=C(NC(=O)C1=CN=C(N)N=C1)N1CCN=C21 |
Pathways | |
PharmGKB | |
ChEMBL | CHEMBL3218576 |